U.S. Markets closed

DEADLINE TODAY: Goldberg Law PC Announces a Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

LOS ANGELES, Sept. 29, 2017 /PRNewswire/ -- Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against IntelliPharmaCeutics International Inc. ("IntelliPharmaCeutics" or the "Company") (IPCI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's shares between January 14, 2016 and July 26, 2017, inclusive (the "Class Period"), are encouraged to contact the firm by September 29, 2017, the lead plaintiff motion deadline.

If you are a shareholder who suffered a loss during the Class Period, click here to participate.

We also encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights free of charge. You can also reach us through the firm's website at http://www.goldberglawpc.com/, or by email at info@goldberglawpc.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Complaint alleges that during the Class Period, IntelliPharmaCeutics made false and/or misleading statements, and/or failed to disclose material information about its business and prospects. On July 24, 2017, scientists from the U.S. Food & Drug Administration ("FDA") expressed concerns that the Company failed to provide sufficient data about the abuse potential of its opioid painkilling drug, Rexista. On July 26, 2017, IntelliPharmaCeutics announced that two advisory committees of the FDA voted 22 to 1 to oppose the Company's New Drug Application for Rexista, citing insufficient data regarding the abuse-deterrent properties of the drug as a motivating concern. When this news was announced, the Company's stock price fell materially, which caused investors harm.

Goldberg Law PC represents investors around the world, and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.


Goldberg Law PC, Los Angeles
Michael Goldberg, Esq., 800-977-7401
Brian Schall, Esq., 800-977-7401


View original content:http://www.prnewswire.com/news-releases/deadline-today-goldberg-law-pc-announces-a-securities-class-action-lawsuit-against-intellipharmaceutics-international-inc-and-encourages-investors-with-losses-in-excess-of-100000-to-contact-the-firm-300528288.html